Introduction
Controlled ovarian stimulation using a gonadotrophin-releasing hormone (GnRH) antagonist is a potential treatment option for patients with a low response to fertility treatments, as it appears to be at least as effective as GnRH-agonist treatment (long protocol) (1) .
Controlled ovarian stimulation with a GnRH antagonist offers a number of advantages compared with the long agonist protocol, including a reduction in the overall duration of the treatment, the absence of peri-menopausal symptoms as a result of pituitary desensitization, no risk of inadvertent GnRH Pretreatment with oral contraceptive pills to identify poor responders that may benefit from rLH supplementation during GnRH-antagonist treatment for IVF: A pilot perspective study proposal agonist administration at the early stages of pregnancy, no risk of ovarian cyst formation during the mild luteal phase and reduced doses of gonadotropins (2) . Therefore, in low responders, ovarian stimulation without pituitary suppression may induce asynchronous follicular development with a limited degree of potential follicle development. Furthermore, in patients that are predicted to be poor responders, for example with elevated serum levels of basal follicle-stimulating hormone (FSH) due to a decreased ovarian reserve, antral follicle sizes during the early follicular phase are often markedly heterogeneous. This phenomenon is associated with the early exposure of FSH-sensitive follicles to gradient FSH concentrations during the previous luteal phase.
A potential disadvantage of GnRH-antagonist protocols is that stimulation is generally initiated on days 2 or 3 of the menstrual cycle, which increases the difficulty of planning stimulation and laboratory activities. However, cycle scheduling may be used to avoid having to retrieve oocytes at the weekend and to distribute the workload equally throughout the week, thereby reducing the disturbance of incubators and the associated negative impact on embryonic development. Furthermore, it can reduce the amount of unplanned laboratory work, which may adversely affect the concentration and efficiency of laboratory staff (3) .
Oral contraceptive pills (OCPs) and synthetic progestogens have previously been used to schedule the ovarian stimulation cycle (4) (5) (6) . Estrogens primarily inhibit FSH secretion, whereas progestogens primarily control luteinizing hormone (LH) secretion. The mechanisms underlying this process have not been well defined; however, it has been postulated that the gestagen component of OCPs may exert a negative impact on endometrial receptivity in the subsequent cycle. Alternatively, low concentrations of LH following OCP pretreatment may impair oocyte quality or endometrial receptivity if ovarian stimulation is performed using recombinant FSH (rFSH) but no LH is administered (4) (5) (6) .
According to in vitro fertilization (IVF) stimulation protocols, GnRH antagonists are administered to prevent a premature pituitary LH surge, which exerts a detrimental effect in patients that undergo IVF. Treatment with GnRH antagonists may result in reduced gonadotropin levels. In order to facilitate follicle growth, FSH is administered exogenously, whereas LH is not typically administered. Although GnRH antagonists prevent surges in LH levels, there is evidence that the administration of GnRH analogs may result in an excessive reduction in endogenous LH levels, particularly in older women (7, 8) . A number of studies have been performed to investigate whether the additional administration of recombinant LH (rLH) with rFSH is able to improve the ovarian stimulation cycle outcome (9, 10) . Few studies have analyzed this factor in the context of GnRH antagonist treatment, and the results of these trials obtained in older women (>35-years-old) are inconsistent (11) .
The use of rLH supplementation during ovarian stimulation, as a part of an assisted reproductive technique (ART), has not been demonstrated to increase pregnancy success rate, and previous studies have reported conflicting results in women aged ≥35 years. Previous results do not support the hypothesis that the addition of rLH increases the rate of pregnancy in unselected patients treated with an ART protocol consisting of rFSH with a GnRH antagonist. There may be a potential benefit associated with the use of rLH supplementation during ovarian stimulation in women who have a poor response or are of an advanced age (12) .
Therefore, it may be valuable to conduct a study focused on women aged ≥40 years, with the aim of determining if women may be able to benefit from rLH supplementation during ovarian stimulation and identifying the cohort of women that would benefit, in order to improve IVF outcome.
In previous literature, the only study conducted in women >35 years old that received a GnRH antagonist protocol, postulated that the degree of hypothalamic-pituitary-ovarian recovery following pretreatment with OCP administration, may be used to identify patients that could benefit from rLH supplementation (13) . However, to date no such perspective randomized study has been conducted to investigate this topic.
Materials and methods
Presentation of the hypothesis. The currently proposed hypothesis is based on rationale that, in older women that are predicted to respond poorly to GnRH antagonist protocols, the extent to which serum levels of endogenous gonadotrophins are returned to normal by action of the hypothalamic-pituitary-ovarian axis following pretreatment with OCPs may be useful for identifying whether women may benefit from rLH supplementation, and if so, which ones.
In certain cases, older women who are predicted to be poor responders exhibit an altered hypothalamic-pituitary-ovarian regulatory mechanism due to the dysregulation of E2 feedback. The aberrant responsiveness of the hypothalamic-pituitary axis to estrogen feedback and the subsequent generation of abnormal patterns of gonadotropin release (normal, attenuated or increased) may accelerate spontaneous ovarian follicular depletion and reduce the likelihood of a good ovarian responsiveness during controlled ovarian hyperstimulation.
We hypothesize that patients with suppressed activity of the hypothalamic-pituitary axis may benefit from rLH supplementation, as GnRH antagonist administration during ovarian stimulation has the potential to induce a marked reduction in LH levels in such patients compared with that in patients with a regular recovery of the activity of this axis following OCP.
Furthermore, we hypothesize that patients with hyper-responsiveness of hypothalamic-pituitary-axis activity following OCP may be affected by 'low gonadotropin responsiveness' comparable to that in patients with a mutation in the FSH receptor (14) . Thus, such cases may benefit from the ability of rLH supplementation to potentiate exogenous FSH activity in theca and granulosa cells.
Therefore, the primary aim of the currently proposed study is to determine whether 1 month pretreatment with OCP is useful for detecting the cohort of women in a pool of estimated poor responders aged >40 years that may benefit from rLH supplementation during the ovarian stimulation cycle according to hypothalamic-pituitary-ovarian recovery after OCP administration. A secondary aim of the proposed study is to detect the most effective serum markers for assessing the cohort of patients that may benefit from rLH administration during ovarian stimulation.
Testing the hypothesis. The proposed pilot study will include 120 women aged between 40 and 50 years, that are predicted to be poor responders according to the Bologna Criteria (15), with an ovarian biological age higher than their chronological age (16) (17) (18) . Patients who have not previously undergone a first fresh non-donor IVF cycle for primary infertility without rLH supplementation during ovarian stimulation will be excluded.
All enrolled patients will be properly informed regarding the aims of the study, and will be required to agree to these aims and to the use of their data according to the Italian Law for Privacy 675/96 prior to enrolment.
Patients with any of the following characteristics will be excluded: History of smoking, deep endometriosis with elevated CA125 serum value (19) , previous ART cycle in the preceding 3 months, BMI >30, karyotype abnormalities, mutations of the cystic fibrosis gene, acquired or inherited thrombophilia and immunological disorders, previous chemotherapy and/or radiotherapy for neoplasia treatment and marked qualitative and quantitative alteration in the semen used for fertilization, according to World Health Organization guidelines (20) .
In cases of benign uterine lesions, such as endometrial polyps, submucous myomas, intrauterine synechiae and/or uterine septus, patients will be considered eligible for the study if they have undergone hysteroscopic-adequate treatment at least 3 months previously (21) (22) (23) .
All women, accurately selected according to the exclusion criteria, will be assigned at random (using 2:1 computerized randomization) to one of two study groups: Group A (OCP-treated) or group B (control).
Group A patients will be pre-treated with OCPs containing 2 mg dienogest and 0.03 mg ethinyl estradiol (Effiprev ® ; Effik Italia SpA, Milan, Italy) for 21 days during the menstrual cycle prior to the scheduled IVF/intra-cytoplasmic sperm injection.
For all patients, serum values of FSH, LH and E2 will be determined on day 3 of the cycle preceding OCP, considered as the basal values, and at the beginning of stimulation (4 days after the final OCP for group A patients and 4 days after the initiation of menses for group B patients).
Single absolute numbers and Δ-variation from baseline (expressed as a percentage) will be considered for all markers, the FSH/LH ratio and the E2/FSH ratio in the blood samples.
Δ-variation from the baseline FSH and LH values will be used to categorize patients into one of four quartiles (Q1, Q2, Q3 and Q4), in a similar manner to the study proposed by Schmitz et al (24) .
Patients will be classified based on the following criteria: Q1, patients with negative baseline variation >25%; Q2, patients with negative baseline variation between 5 and 25%; Q3, patients with positive baseline variation between 5 and 25%; and Q4, patients with positive baseline variation >25%.
According to their obtained FSH quartile, patients will be admitted to the subgroup A1 in cases of Q1, to subgroup A2 in cases of Q2, to subgroup A3 in cases of Q3 and to subgroup A4 in cases of Q4. Patients admitted to each of the subgroups A1-4 (n=20 per subgroup) will be secondly randomized to determine whether they will receive rLH supplementation (ratio, 1:1) during ovarian stimulation, starting from day 4 of stimulation. A detailed flow chart of the proposed study protocol is shown in Fig. 1 .
Patients in groups A and B will be treated with GnRH-antagonist (short protocol) stimulation according to our Units Protocol (25, 26) . All stimulation cycles will be performed using 350 IU rFSH (Gonal F; Merck Serono S.A., Geneva, Switzerland) daily for the first 5 days. Subsequent adjustments to the treatment will be decided by the clinicians according to ovarian response and various biochemical and ultrasound features. In addition, 0.25 mg GnRH antagonist (Ganirelix; MSD Italia S.R.L., Rome, Italy) will be administered daily, starting from the ultrasonographic detection of at least one follicle of >14 mm diameter and continued until human chorionic gonadotropin (hCG) administration.
Starting at day 6 of stimulation, all patients will undergo serum sampling for the measurement of hormone levels (17β estradiol, progesterone and LH) and pelvic ultrasound.
After an adequate number of follicles (≥3 follicles with a diameter of >18 mm) have been detected, 250 µg recombinant hCG (r-hCG) (Ovitrelle; Merck Serono S.A.) will be administered to induce ovulation.
Oocyte retrieval will be conducted at 36 h after hCG administration. Oocytes will be fertilized according to standard IVF techniques.
Between 1 and 3 embryos will be transferred on days 2 to 3 following oocyte retrieval. The number of embryos transferred will be determined on the basis of the age of the patient and embryo quality.
Furthermore, 400 mg vaginal progesterone (Progeffik; Effik Italia SpA) will be administered daily as a luteal support until day 14 after oocyte retrieval, and the treatment will be discontinued in the event of a negative β-hCG serum test.
Pregnancy will be confirmed by the detection of increased β-hCG concentrations at week 2 after embryo transfer (ET) and with sonographic observation of an intrauterine gestational sac at weeks 3-4 after ET. Continuing pregnancy will be confirmed by the detection of an embryo heart beat with transvaginal sonography.
The primary aim of the proposed study is to compare the following parameters between groups A and B: Number of IVF cycles that are cancelled prior to ovarian stimulation (due to a basal E2 value of >300 pmol/l) and during ovarian stimulation (due to <3 follicles with a diameter of >14 mm); total dose of rFSH administered during ovarian stimulation (IUs); length of stimulation (days); total number of follicle and number of follicles >14 mm in diameter; total number of retrieved oocytes and number of mature oocytes; number and quality of obtained embryos, endometrial thickness at oocyte retrieval; pregnancy rate; and continuing pregnancy rate.
A secondary aim of the study is to compare the following parameters among the four A subgroups: Total dose of rFSH administered during ovarian stimulation (IUs), length of stimulation (days), total number of follicle and number of follicles >14 mm in diameter, total number of retrieved oocytes and number of mature oocytes, number and quality of obtained embryos, endometrial thickness at oocyte retrieval, pregnancy rate and continuing pregnancy rate in order to detect which, if any, FSH quartile will be a predictor of an improved IVF outcome.
Finally, a third intended outcome is to detect whether rLH supplementation improves the IVF outcomes in each subgroup-A patient, determine in which of the interquartile subgroups A1-4 the rLH supplementation produces the most improved results and identify whether variations in other serum markers after OCP have a greater predictive capability than the FSH serum value in the detection of patients that may benefit from rLH supplementation. Detailed steps of the proposed study protocol are summarized in Fig. 1 .
Statistical analysis will be performed using SPSS software for Windows, version 19.0 (IBM SPSS, Armonk, USA), applying parametric and non-parametric tests when appropriate. The Kolmogorov-Smirnov test will be used to assess the normality of distribution. Continuous variables will be expressed as absolute numbers, the mean ± standard deviation, and will be analyzed using Student's t-test or analysis of variance when appropriate. Categorical variables will be expressed as percentages and analyzed using the χ 2 test or Fisher's exact test. P<0.05 will be considered to indicate a statistically significant difference.
Discussion
If the current hypothesis is confirmed, it should facilitate the identification of women that could benefit from rLH supplementation during ovarian stimulation, among the cohort of predicted poor responders. Consequently, previous inconclusive results concerning rLH supplementation may be clarified.
If patients supplemented with rLH (according to abnormal recovery of the activity of the hypothalamic-pituitary axis following OCP treatment) display improvements in terms of ovarian response during IVF and subsequently pregnancy rate, the OCP test pre-IVF may be considered to be a useful tool for improving the success of ARTs in poor responders, reducing cost and patient stress.
It is reasonable to expect that the number of patients that consent to the 1-month OCP study will be high, as the proposed study involves a low-expense, well-tolerated intervention, with no obvious contraindications.
If the predictive efficacy of the OCP-test is confirmed, its use in patients prior to GnRH antagonist protocols to detect patients requiring rLH supplementation during ovarian stimulation may be extended to a large scale population.
